Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients

Background Opioid-induced constipation (OIC) has become more common in the intensive care unit (ICU) due to increased opioid utilization. Traditional laxatives often prove ineffective against OIC, leading utilization of naloxegol. However, further research is needed confirm naloxegol's effectiveness and safety critical care. This study aimed explore efficacy this intervention critically ill OIC patients. Methods A single-center retrospective was conducted on 353 patients who received one or doses naloxegol from January 1, 2019, June 30, 2020, for at a tertiary center. The primary endpoint evaluate serious adverse events such as reduced analgesic effect, gastrointestinal perforation, seizure, acute myocardial infarction (AMI), ventricular arrhythmias using Naranjo Scale secondary goal assess naloxegol, measured by time first bowel movement. Results average duration use three days, with movement occurring an 11.3 hours. Furthermore, 59.8% individuals had their within 20 hours receiving There low level causality between seizures, AMI, cardiovascular mortality, stroke, arrhythmia. Additionally, reduction analgesia showed no strong relationship indicated assessment. Conclusion Naloxegol promising profiles treating amongst patients, though our findings require validation through prospective studies. paves way investigation into naloxegol’s role management, emphasizing necessity personalized treatment strategies settings.